Literature DB >> 28324004

Bone Turnover Is Suppressed in Insulin Resistance, Independent of Adiposity.

Katherine T Tonks1,2,3, Christopher P White4,3, Jacqueline R Center2,5,3, Dorit Samocha-Bonet1,3, Jerry R Greenfield1,2,3.   

Abstract

CONTEXT: The contribution of insulin resistance vs adiposity to bone mineral density (BMD), bone turnover, and fractures in humans remains unclear.
OBJECTIVE: To evaluate BMD and bone turnover markers (BTMs) in lean (n = 18) and overweight/obese individuals with (n = 17) and without (n = 34, insulin-sensitive [Obsensitive, n=15] or insulin-resistant [Obresistant, n=19] by homeostasis model assessment insulin resistance) diabetes mellitus.
DESIGN: Observational study. OUTCOME MEASURES: Insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp; whole body BMD and fat mass (FM) using dual energy X-ray absorptiometry; and by measurement of BTMs [osteocalcin (OC), procollagen type 1 N-terminal propeptide (P1NP), and collagen type 1 cross-linked C-terminal telopeptide (CTx)], with the patient fasting and during clamp hyperinsulinemia.
RESULTS: Fasting BTMs correlated with glucose infusion rate/fat-free mass (GIR/FFM) and adiponectin and, inversely, with fasting insulin and visceral fat (P ≤ 0.04 for all). Obsensitive, Obresistant, and diabetic individuals were matched by their FM percentage. Clamp GIR/FFM was similar in the lean and Obsensitive subjects (P = 1) and approximately twofold greater (P < 0.001) than in the Obresistant and diabetic subjects. BMD was greater in Obresistant than in Obsensitive (P = 0.04) and lean (P = 0.001) subjects. At baseline, compared with Obsensitive and lean subjects, Obresistant and diabetic individuals had lower OC, P1NP, and CTx levels. This reached statistical significance for Obresistant vs lean and Obresistant vs Obsensitive for both OC and CTx and for diabetic vs lean for CTx (P ≤ 0.04 for all). During hyperinsulinemia, lean individuals suppressed CTx more than did diabetic individuals (P = 0.03). On multiple regression analysis, visceral adiposity explained 16.7% and 19.3% of the baseline OC and CTx variability, respectively.
CONCLUSIONS: Increased visceral adiposity and higher fasting insulin in insulin-resistant states are associated with lower fasting OC and CTx and failure to further suppress with more insulin.
Copyright © 2017 by the Endocrine Society

Entities:  

Mesh:

Year:  2017        PMID: 28324004     DOI: 10.1210/jc.2016-3282

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

1.  Effect of Insulin Resistance on BMD and Fracture Risk in Older Adults.

Authors:  Nicola Napoli; Caterina Conte; Claudio Pedone; Elsa S Strotmeyer; Kamil E Barbour; Dennis M Black; Elizabeth J Samelson; Ann V Schwartz
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

Review 2.  Update on the Acute Effects of Glucose, Insulin, and Incretins on Bone Turnover In Vivo.

Authors:  Vanessa D Sherk; Irene Schauer; Viral N Shah
Journal:  Curr Osteoporos Rep       Date:  2020-08       Impact factor: 5.096

3.  Effects of Biliopancreatic Diversion on Bone Turnover Markers and Association with Hormonal Factors in Patients with Severe Obesity.

Authors:  Anne-Frédérique Turcotte; Thomas Grenier-Larouche; Roth-Visal Ung; David Simonyan; Anne-Marie Carreau; André C Carpentier; Fabrice Mac-Way; Laetitia Michou; André Tchernof; Laurent Biertho; Stefane Lebel; Simon Marceau; Claudia Gagnon
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

Review 4.  Assessment of bone quality in patients with diabetes mellitus.

Authors:  N Jiang; W Xia
Journal:  Osteoporos Int       Date:  2018-05-07       Impact factor: 4.507

Review 5.  Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus.

Authors:  Sundeep Khosla; Parinya Samakkarnthai; David G Monroe; Joshua N Farr
Journal:  Nat Rev Endocrinol       Date:  2021-09-13       Impact factor: 47.564

6.  The relationship between estimated glucose disposal rate and bone turnover markers in type 2 diabetes mellitus.

Authors:  Zelin Li; Cuijuan Qi; Xiaoyu Pan; Yujiao Jia; Xuetong Zhao; Chenqian Deng; Shuchun Chen
Journal:  Endocrine       Date:  2022-06-14       Impact factor: 3.925

7.  Hepatocyte growth factor administration increases bone soluble phosphate and alters bone chemical structure in diabetic hypertensive rats.

Authors:  Kamal Awad; Natasha G Boyes; Ramlah Iqbal; Mohamed Ahmed; Adel Mohamed; Pranesh Aswath; Corey R Tomczak; Venu Varanasi
Journal:  J Mater Res       Date:  2021-07-23       Impact factor: 2.909

8.  Higher serum uric acid is associated with higher lumbar spine bone mineral density in male health-screening examinees: a cross-sectional study.

Authors:  Jiwon Hwang; Jung Hye Hwang; Seungho Ryu; Joong Kyong Ahn
Journal:  J Bone Miner Metab       Date:  2018-01-25       Impact factor: 2.626

9.  Biochemical Markers of Bone Turnover and Risk of Incident Diabetes in Older Women: The Cardiovascular Health Study.

Authors:  Daniele Massera; Mary L Biggs; Marcella D Walker; Kenneth J Mukamal; Joachim H Ix; Luc Djousse; Rodrigo J Valderrábano; David S Siscovick; Russell P Tracy; Xiaonan Xue; Jorge R Kizer
Journal:  Diabetes Care       Date:  2018-07-12       Impact factor: 19.112

10.  FSH may mediate the association between HbA1c and bone turnover markers in postmenopausal women with type 2 diabetes.

Authors:  Ke-Xi Zha; Zeng-Mei An; Shao-Hong Ge; Jian Cai; Ying Zhou; Rong Ying; Ji Zhou; Tao Gu; Hui Guo; Yan Zhao; Ning-Jian Wang; Ying-Li Lu
Journal:  J Bone Miner Metab       Date:  2022-01-21       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.